Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a steroid injection tame the inflammation behind retinal detachment?

NCT ID NCT07774182

Disease control Sponsor: Anggun Rama Yudantha Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether a steroid injection given about a week before surgery can reduce harmful inflammation and scarring in people with retinal detachment. Participants are randomly assigned to receive either the injection plus standard surgery or surgery alone. The study measures levels of inflammatory markers in eye fluids and imaging changes to see if the injection helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Triamcinolone acetonide, an anti-inflammatory steroid, injected into the eye before surgery.
What this could lead to
If effective, this could reduce scarring and improve surgical outcomes for people with retinal detachment.
What could go wrong
This is a small, early-stage trial, and the steroid may not significantly change biomarkers or clinical outcomes. Risks include infection, increased eye pressure, and cataract progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

May 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older with rhegmatogenous retinal detachment (RRD) and proliferative vitreoretinopathy (PVR) grade B or C. * No previous history of rhegmatogenous retinal detachment. * No requirement for surgical intervention other than treatment for RRD. * Willingness to participate in all study procedures and provide written informed consent. Exclusion Criteria: * RRD with vitreous opacity precluding adequate fundus examination. * RRD caused by a giant retinal tear. * History of cataract surgery within the previous 3 months. * RRD associated with other ocular comorbidities. * Systemic disease that precludes vitrectomy. * History of ocular hypertension or glaucoma. * RRD with a cloudy lens requiring cataract surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Proliferative vitreoretinopathy in rhegmatogenous retinal detachment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Camurati-Engelmann Syndrome proliferative vitreoretinopathy rhegmatogenous retinal detachment

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Proliferative vitreoretinopathy in rhegmatogenous retinal detachment

Contacts and locations

Locations

  • Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta

    Jakarta, DKI Jakarta, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.